California Public Employees Retirement System Has $206.72 Million Stock Position in Stryker Corporation $SYK

California Public Employees Retirement System cut its stake in Stryker Corporation (NYSE:SYK) by 6.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 629,128 shares of the medical technology company’s stock after selling 45,241 shares during the period. California Public Employees Retirement System’s holdings in Stryker were worth $206,725,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Stryker during the 4th quarter worth about $1,822,272,000. Auto Owners Insurance Co lifted its stake in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. Wellington Management Group LLP lifted its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Corient Private Wealth LLC boosted its position in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Credit Agricole S A acquired a new stake in Stryker during the third quarter worth approximately $194,045,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SYK shares. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Wells Fargo & Company cut their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. BMO Capital Markets started coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $392.52.

Stryker Stock Performance

Shares of Stryker stock opened at $319.78 on Friday. The business has a 50-day simple moving average of $312.69 and a 200 day simple moving average of $336.82. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market capitalization of $122.59 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.